MARKET

PCSA

PCSA

Processa Pharmaceuticals Inc
NASDAQ
2.603
+0.078
+3.09%
After Hours: 2.610 +0.007 +0.27% 17:26 04/01 EDT
OPEN
2.510
PREV CLOSE
2.525
HIGH
2.730
LOW
2.510
VOLUME
15.49K
TURNOVER
--
52 WEEK HIGH
19.63
52 WEEK LOW
1.760
MARKET CAP
6.92M
P/E (TTM)
-0.2513
1D
5D
1M
3M
1Y
5Y
1D
Processa R&D President David Young buys PCSA shares worth $0 million
Reuters · 2h ago
Processa CFO Russell Skibsted acquires $0m common shares of Processa Pharmaceuticals
Reuters · 2h ago
Processa director Geraldine Pannu buys $0m in common shares
Reuters · 2h ago
Processa CEO George Ng acquires $0 common shares
Reuters · 2h ago
Processa Chief Business Strategy Officer Patrick Lin buys 1,603 shares for $0 million
Reuters · 2h ago
Processa Chief Administrative Officer Wendy Guy acquires $0m common shares
Reuters · 2h ago
Processa Chief Development Officer Sian Bigora acquires PCSA shares worth $0m
Reuters · 3h ago
Processa director Baluch Khoso buys USD 5.8 million common shares
Reuters · 3h ago
More
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

Webull offers Processa Pharmaceuticals Inc stock information, including NASDAQ: PCSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCSA stock methods without spending real money on the virtual paper trading platform.